Korro Bio, Inc. ( (KRRO) ) has released its Q1 earnings. Here is a breakdown of the information Korro Bio, Inc. presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Korro Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing RNA editing technologies to treat rare and prevalent diseases, operating primarily in the biotechnology sector. The company recently released its earnings report for the first quarter of 2025, highlighting a net loss of $23.4 million, compared to a $19.6 million loss in the same period last year. Despite the losses, Korro Bio reported collaboration revenue of $2.6 million, primarily from its agreement with Novo Nordisk. Key financial metrics include cash and cash equivalents of $64.1 million, with total assets amounting to $202.2 million. The company continues to invest heavily in research and development, with expenses reaching $19.7 million for the quarter. Looking ahead, Korro Bio remains focused on advancing its clinical trials and research programs, with management optimistic about reaching meaningful clinical data milestones in the future.